FDA Inspection 1070430 — U.S. Continental Marketing, Inc.

U.S. Continental Marketing, Inc. — FEI 3005519645

The FDA completed an inspection of U.S. Continental Marketing, Inc. on October 30, 2018 in Corona, CA. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 6 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
October 30, 2018
Fiscal Year
2019
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Corona, CA (United States)

Citations

IDCFRDescription
111221 CFR 211.25(a)Training--operations, GMPs, written procedures
122721 CFR 211.67(c)Cleaning/maintenance records not kept
154021 CFR 211.125(a)Strict control not exercised over labeling issued
204421 CFR 211.196Distribution Record Requirements
430621 CFR 211.80(a)Written Procedures Not Followed
437321 CFR 211.188(b)(7)Actual yield, % of theoretical yield